In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Dr. RJ Tesi, CEO of INmune Bio about its clinical program that seeks to determine whether its existing TNF inhibitors can be repurposed to prevents complications of cytokine storm caused by COVID-19. Dr. Tesi gives solemn insight into trial design, endpoint selection, FDA application as well explaining how INmune is “messing” with the pathology of COVID-19, not only to treat its symptoms but to treat the disease itself. Dr. Tesi takes us through the evolving landscape of secondary complications caused by COVID-19 and leaves us with the anecdote that many in the industry are beginning to understand; “to know COVID-19 is to know medicine." Hosted on Acast. See acast.com/privacy for more information.